Online inquiry

IVTScrip™ mRNA-Anti-IL33, REGN-3500(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) (CAT#: GTTS-WQ14012MR)

This product GTTS-WQ14012MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets IL33 gene. The antibody can be applied in Chronic Obstructive Pulmonary Disease (COPD) research.

Specifications
Product type	mRNA
Modified bases	5-Methoxy-UTP
5' Cap	Cap 1
Species	Homo sapiens; Humanized
RefSeq	NM_001199640.2
Applications	Gene therapy research
Format	Powder
Quantity	100 µg
Purification	oligo-dT affinity purification

Target Gene
Gene ID	90865
UniProt ID	O95760

Download
Download resources about mRNA therapeutics development to boost your research.

CUSTOMER REVIEWS and Q&As
There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL33, REGN-3500(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ14012MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT	Product Name	Product Type	CDs
GTTS-WQ6806MR	IVTScrip™ mRNA-Anti-STEAP1, DSTP-3086S(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))	mRNA	DSTP-3086S
GTTS-WQ10995MR	IVTScrip™ mRNA-Anti-CD79B, MCDS0593A(Cap 0, 2-Thio-UTP, 120 nt-poly(A))	mRNA	MCDS0593A
GTTS-WQ6134MR	IVTScrip™ mRNA-Anti-CTLA4, CP-675(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))	mRNA	CP-675
GTTS-WQ389MR	IVTScrip™ mRNA-Anti-TYRP1, 20D7S(Cap 0, 2-Thio-UTP, 30 nt-poly(A))	mRNA	20D7S
GTTS-WQ1684MR	IVTScrip™ mRNA-Anti-IL1B, ACZ885(Cap 1, 2-Thio-UTP, 120 nt-poly(A))	mRNA	ACZ885
GTTS-WQ13493MR	IVTScrip™ mRNA-Anti-IgG-Fc, PRTX-100(Cap 1, Pseudo-UTP, 30 nt-poly(A))	mRNA	PRTX-100
GTTS-WQ11734MR	IVTScrip™ mRNA-Anti-IGF1R, MK-0646(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))	mRNA	MK-0646
GTTS-WQ14646MR	IVTScrip™ mRNA-Anti-DLL3, SC0001-SCX(Cap 1, 2-Thio-UTP, 30 nt-poly(A))	mRNA	SC0001-SCX

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST